TURKISH JOURNAL OF ONCOLOGY 2008 , Vol 23 , Num 4
Preoperative radiotherapy with concomitant fluoropyrimidine-based chemotherapy for resectable locally advanced rectal cancer
Beste Melek ATASOY1, Faysal DANE2, Hale ÇAĞLAR1, Evrim TEZCANLI3, Asım CİNGİ4, Ufuk ABACIOĞLU1, Serdar TURHAL2, Cumhur YEĞEN4
1Marmara Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Turkey
2Marmara Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı Tıbbi Onkoloji Bilim Dalı, İstanbul, Turkey
3Acıbadem Kozyatağı Hastanesi Radyasyon Onkolojisi Kliniği, İstanbul, Turkey
4Marmara Üniversitesi Tıp Fakültesi Genel Cerrahi Anabilim Dalı, İstanbul, Turkey
OBJECTIVES
To investigate the treatment results and tumor and patient characteristics in patients with resectable locally advanced rectum cancer (LARC) who were treated with preoperative chemoradiation.

METHODS
T3/T4 rectal adenocarcinoma patients (n=50) were evaluated retrospectively. Tumors were located within 5 cm of the anal verge in 60% of patients. Twenty-four (48%) of the patients had positive lymph nodes. Pelvic radiotherapy was administered with a median dose of 45Gy in linear accelerator. Concurrent fluoropyrimidine was given orally (n=18) or intravenously (n=32).

RESULTS
Median follow-up was 17 months. Two-year local control, disease- free survival and overall survival were 93.6%, 90.3% and 93.3%, respectively. Sphincter-preserving surgery rate was 43% for distal tumors. Downstaging was observed in 35% with seven ypT0N0 cT4 (p=0.01), lymphovascular-perineural invasion (p=0.01) and pN+ (p=0.02) were predictive for a worse prognosis. Grade 3 toxicity was observed in 8% of patients.

CONCLUSION
Preoperative chemoradiotherapy demonstrated similar benefit regarding sphincter preservation with that of standard postoperative multimodality therapies in LARC patients. Keywords : Chemoradiotherapy; neoadjuvant treatment; rectal cancer; Turkish patients